Hing Lai, MD
Urology · Saint Louis, MONPI 1376676734
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Astellas Pharma Global Development at 40.7% of the total. Reporting peaked in 2021 at $5,890 and has fallen 89.2% since, to $635 in 2025.
Across 81 payments — averaging $167.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma Global Development$6K
- Axonics, Inc.$3K
- Biohaven Pharmaceuticals, Inc.$2K
- Medtronic$2K
- Boston Scientific$354
- Calyxo, Inc.$215
- plus $524 from 8 others
Across 48 payments — averaging $3403.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$147K
- AbbVie$13K
- Astellas Pharma Global Development$4K
What the payments were for
- Consulting fees$7,52555%
- Travel & lodging$2,91821%
- Food & beverage$3,13323%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma Global Development | 5 | $5,525 |
| Axonics, Inc. | 23 | $3,247 |
| Biohaven Pharmaceuticals, Inc. | 1 | $2,000 |
| Medtronic(2 entities) | 17 | $1,711 |
| Boston Scientific | 12 | $354 |
| Calyxo, Inc. | 2 | $215 |
| AbbVie(2 entities) | 9 | $145 |
| Cook Medical LLC | 1 | $129 |
| Astellas Pharma US Inc | 6 | $107 |
| Procept Biorobotics Corporation | 1 | $56 |
| Teleflex LLC | 1 | $27 |
| ABC Home Medical Supply, Inc. | 1 | $23 |
| Tolmar, Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYRBETRIQ$5,525
- Axonics$2,446
- NURTEC ODT$2,000
- Bulkamid$1,471
- INTERSTIM$1,099
- GENERAL ERECTILE DYSFUNCTION$234
- INTERSTIM ICON$197
- CVAC Aspiration System$161
- Cook$129
- Axonics r-SNM System$125
How this compares
$13,575 in reported general payments places this provider in the 85th percentile of 250 urology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 221 | $147,414 |
| GemtesaVibegron | 38 | $21,964 |
| Mirabegron ErMirabegron | 20 | $10,757 |
| ElmironPentosan Polysulfate Sodium | 12 | $4,643 |
| Solifenacin Succinate | 118 | $4,474 |
| Trospium Chloride ErTrospium Chloride | 20 | $2,812 |
| Oxybutynin Chloride ErOxybutynin Chloride | 123 | $2,627 |
| Methenamine Hippurate | 26 | $1,856 |
| Estradiol | 17 | $1,264 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 17 | $974 |
| Tamsulosin Hcl | 79 | $920 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 73 | $822 |
| NitrofurantoinNitrofurantoin Macrocrystal | 22 | $673 |
| Desmopressin Acetate | 15 | $623 |
| Trospium Chloride | 19 | $620 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $107 | $147,414221 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $19 | $21,96438 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 250 urology providers in Missouri.
Other urology in Saint Louis
- Travis BullockSaint Louis$201K
- Michael JohnsonSaint Louis$160K
- Gurdarshan SandhuSaint Louis$101K
- Gregory McLennanSaint Louis$89K
- Gerald AndrioleSaint Louis$64K
- Charles JonesSaint Louis$55K
- Meredith MetcalfSaint Louis$26K
- Maung Htein ThuSaint Louis$22K
- Alexander ChowSaint Louis$20K
- Jonathan WeeseSaint Louis$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.